PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 33743158-0 2021 Piperazine-substituted chalcones: a new class of MAO-B, AChE, and BACE-1 inhibitors for the treatment of neurological disorders. Chalcones 23-32 monoamine oxidase B Homo sapiens 49-54 32299731-1 2020 Literature reports that chalcones inhibit the monoamine oxidase (MAO) enzymes, mostly with specificity for the MAO-B isoform, while nitrocatechol compounds are established inhibitors of catechol-O-methyltransferase (COMT). Chalcones 24-33 monoamine oxidase B Homo sapiens 111-116 33571810-0 2021 Combined 3D-QSAR and docking analysis for the design and synthesis of chalcones as potent and selective monoamine oxidase B inhibitors. Chalcones 70-79 monoamine oxidase B Homo sapiens 104-123 33571810-3 2021 In the current work, we focused our attention on the understanding of theoretical models that may predict the MAO-B activity and selectivity of new chalcones. Chalcones 148-157 monoamine oxidase B Homo sapiens 110-115 32299731-4 2020 The present study expands on the discovery of dual MAO-B/COMT inhibitors by synthesising additional nitrocatechol derivatives of chalcones which include heterocyclic derivatives, and converting them to the corresponding pyrazoline derivatives. Chalcones 129-138 monoamine oxidase B Homo sapiens 51-56 32924264-2 2020 The present work describes the syntheses of selected 1,3-benzodioxine-containing chalcones (CD3, CD8 and CD10), and their inhibitory activities against MAO-A, MAO-B, acetylcholinesterase (AChE), and butyrylcholinesterase (BChE). Chalcones 81-90 monoamine oxidase B Homo sapiens 159-164 32705910-0 2020 Design, synthesis, and evaluation of 1, 4-benzodioxan-substituted chalcones as selective and reversible inhibitors of human monoamine oxidase B. Chalcones 66-75 monoamine oxidase B Homo sapiens 124-143 31550216-0 2019 Ethyl Acetohydroxamate Incorporated Chalcones: Unveiling a Novel Class of Chalcones for Multitarget Monoamine Oxidase-B Inhibitors Against Alzheimer"s Disease. Chalcones 36-45 monoamine oxidase B Homo sapiens 100-119 30663112-2 2019 Our results indicate that morpholine containing chalcones are highly selective MAO-B inhibitors having reversibility properties. Chalcones 48-57 monoamine oxidase B Homo sapiens 79-84 31550216-0 2019 Ethyl Acetohydroxamate Incorporated Chalcones: Unveiling a Novel Class of Chalcones for Multitarget Monoamine Oxidase-B Inhibitors Against Alzheimer"s Disease. Chalcones 74-83 monoamine oxidase B Homo sapiens 100-119 31550216-1 2019 BACKGROUND: Chalcones are considered as the selective scaffold for the inhibition of MAO-B. Chalcones 12-21 monoamine oxidase B Homo sapiens 85-90 31550216-8 2019 Among the substitutentin ring Aof ethyl acetohydroxamate-chalcones (L1-L9), F atom at pposition (L3) showed highest inhibitory effect against hMAO-B. Chalcones 34-66 monoamine oxidase B Homo sapiens 142-148 29697034-10 2018 The chalcones are less potent as inhibitors of MAO with the most potent inhibitor possessing a Ki of 4.6 microM for the in vitro inhibition of human MAO-B. Chalcones 4-13 monoamine oxidase B Homo sapiens 149-154 28245770-4 2017 Chromones are structurally related to a series of coumarins and chalcones, which are well-known inhibitors of MAO-B. Chalcones 64-73 monoamine oxidase B Homo sapiens 110-115 28577983-2 2017 Based on our previous report, the methoxy-substituted with fluorine containing chalcones are promising reversible MAO-B inhibitors, while in the present study, a series of methoxylated chalcones (C1-C9) bearing substitution on the para position of ring B was synthesized and evaluated for their human monoamine oxidase inhibitory activity. Chalcones 79-88 monoamine oxidase B Homo sapiens 114-119 28577983-2 2017 Based on our previous report, the methoxy-substituted with fluorine containing chalcones are promising reversible MAO-B inhibitors, while in the present study, a series of methoxylated chalcones (C1-C9) bearing substitution on the para position of ring B was synthesized and evaluated for their human monoamine oxidase inhibitory activity. Chalcones 185-194 monoamine oxidase B Homo sapiens 114-119 26974383-0 2016 Design and synthesis of novel chalcones as potent selective monoamine oxidase-B inhibitors. Chalcones 30-39 monoamine oxidase B Homo sapiens 60-79 27902880-1 2016 Numerous studies have shown that chalcones are promising scaffolds for the development of new monoamine oxidase-B (MAO-B) inhibitors. Chalcones 33-42 monoamine oxidase B Homo sapiens 94-113 27902880-1 2016 Numerous studies have shown that chalcones are promising scaffolds for the development of new monoamine oxidase-B (MAO-B) inhibitors. Chalcones 33-42 monoamine oxidase B Homo sapiens 115-120 27402375-2 2016 In our previous study, we have shown that a series of methoxylated chalcones with F functional group exhibited high binding affinity toward human monoamine oxidase-B (hMAO-B). Chalcones 67-76 monoamine oxidase B Homo sapiens 146-165 27402375-2 2016 In our previous study, we have shown that a series of methoxylated chalcones with F functional group exhibited high binding affinity toward human monoamine oxidase-B (hMAO-B). Chalcones 67-76 monoamine oxidase B Homo sapiens 167-173 26974383-1 2016 A novel series of substituted chalcones were designed and synthesized to be evaluated as selective human MAO-B inhibitors. Chalcones 30-39 monoamine oxidase B Homo sapiens 105-110 26429556-4 2016 CONCLUSION: Many of the studies clearly revealed that most of the chalcones showed selective, reversible and potent MAO-B inhibition compared to MAO-A. Chalcones 66-75 monoamine oxidase B Homo sapiens 116-121 19378991-1 2009 A large series of substituted chalcones have been synthesized and tested in vitro for their ability to inhibit human monoamine oxidases A and B (hMAO-A and hMAO-B). Chalcones 30-39 monoamine oxidase B Homo sapiens 156-162 26432037-9 2015 We conclude that high potency chalcones such as 4h represent suitable leads for the development of MAO-B inhibitors for the treatment of Parkinson"s disease and possibly other neurodegenerative disorders. Chalcones 30-39 monoamine oxidase B Homo sapiens 99-104 24169316-6 2013 The chromenylchalcone scaffold, which is derived from natural products including isoflavonoids and chalcones, had not been previously reported as an MAO-B inhibitor. Chalcones 99-108 monoamine oxidase B Homo sapiens 149-154 34262643-0 2021 Promising Non-cytotoxic Monosubstituted Chalcones to Target Monoamine Oxidase-B. Chalcones 40-49 monoamine oxidase B Homo sapiens 60-79 32920430-0 2020 Chalcones: Unearthing their therapeutic possibility as monoamine oxidase B inhibitors. Chalcones 0-9 monoamine oxidase B Homo sapiens 55-74 34397324-0 2021 Development of 2D, 3D-QSAR and Pharmacophore Modeling of Chalcones for the Inhibition of Monoamine Oxidase B. Chalcones 57-66 monoamine oxidase B Homo sapiens 89-108 34397324-3 2021 METHODS: With the experimental results of about 70 chalcone derivatives, we further developed a pharmacophore modelling, and 2D and 3D- QSAR analyses of these reported chalcones for MAO-B inhibition. Chalcones 168-177 monoamine oxidase B Homo sapiens 182-187 34477522-8 2021 Chalcones, generally, are potential and more selective towards MAO-B inhibitions whereas pyrazolines derived from chalcones turned into selective towards MAO-A inhibitions due to maybe the presence of two nitrogen heteroatoms. Chalcones 0-9 monoamine oxidase B Homo sapiens 63-68